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ABSTRACT
This study evaluated whether amifostine protects against mucositis and other toxicities in patients with
advanced, refractory, or recurrent hematologic malignancies undergoing high-dose chemotherapy and total
body irradiation. Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with
acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total
body irradiation 2 Gy twice daily on days 8 through 6; cyclophosphamide 6 g/m2, etoposide 1.8 g/m2, and
carboplatin 1 g/m2 on days 5 through 3; and amifostine 500 mg/m2 on days 8 through 2. Prior
institutional experience in patients treated without amifostine was used as a historical comparison (no-
amifostine group). Severe mucositis occurred in 14 (40%) of 35 patients in the amifostine group, compared
with 33 (94%) of 35 in the no-amifostine group (P < .0001). Total parenteral nutrition was used by 4 (11%)
of 35 amifostine-treated patients and 34 (97%) of 35 no-amifostine patients (P < .0001). The median duration
of narcotic use decreased from 15.5 days with no amifostine to 11 days with amifostine (P .002). Granulocyte
and platelet engraftment times were similar. Prospective trials with innovative designs and clearly defined
stopping rules are warranted to confirm whether amifostine reduces the toxicities of a myelosuppressive
conditioning regimen before autologous stem cell transplantation without compromising therapeutic re-
sponse.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Mucositis is a signiﬁcant dose-limiting complica-
ion in cancer treatment. The global incidence of
ucositis related to cancer therapy is estimated at
00 000 annually [1]. Mucositis occurs with an overall
ncidence of approximately 30% to 40% during che-
otherapy, and severe, debilitating mucositis is more
ommon with conditioning regimens for hematopoi-
tic stem cell transplant [2]. For high-dose chemo-
herapy, the incidence is much higher and exceeds
0% in some studies [3-7].
Identiﬁcation of reliable risk factors to predict the
everity and sequelae of mucositis is limited, in part
ecause of the lack of uniform mucositis evaluation l
022riteria [8-14]. Despite these drawbacks, the develop-
ent of mucositis models to investigate the effects of
nﬂammatory cytokines and new therapeutic interven-
ions to counter these effects shows promise for re-
uction of both the incidence and the severity of
ucositis [2].
Signiﬁcant improvement in the prevention of mu-
ositis may evolve from exploitation of differences
etween healthy and tumor tissue. The delivery of
herapy in doses sufﬁcient to completely eradicate the
umor typically exceeds the tolerance of healthy tissue,
hereby limiting dose escalation to a level that is suf-
cient for cure [5,15]. Damage to healthy tissue has
he consequence of increased patient morbidity, a
onger hospital stay, and a negative economic effect
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B5,15,16]. Thus, selective targeting of healthy tissue
or cytoprotection, exploiting differences in apoptosis
etween healthy and tumor cells, and minimizing in-
ections are all important issues for investigation.
Amifostine (Ethyol; MedImmune Oncology, Inc.,
aithersburg, MD) is an aminothiol that selectively
rotects healthy tissues against the cumulative renal
oxicity associated with platinum therapy [17] and the
oderate to severe xerostomia associated with irradi-
tion of the parotid glands [18]. This study was un-
ertaken in patients with advanced refractory hema-
ologic malignancies to determine whether amifostine
ould protect against mucositis and other toxicities
ithout compromising the therapeutic response in
atients undergoing a conditioning regimen that in-
luded high-dose chemotherapy and total body irra-
iation (TBI) before autologous stem cell transplan-
ation.
ATIENTS AND METHODS
atients
Patients with non-Hodgkin lymphoma (NHL) or
odgkin disease (HD) were eligible for this study if
heir disease progressed or recurred after at least 1
ourse of combination chemotherapy. Patients with
cute myelogenous leukemia (AML) were eligible if
hey had a high-risk ﬁrst remission or a subsequent
omplete remission (CR). High risk was deﬁned as
isease that necessitated a second induction therapy to
chieve a CR, unfavorable cytogenetics, or extramed-
llary disease. Eligibility criteria also included age
16 and 65 years, an Eastern Cooperative Oncol-
gy Group performance status of 0 to 2, a white blood
ell (WBC) count 1.5  109/L, an absolute neutro-
hil count (ANC) 0.5  109/L, a platelet count 50
109/L, aspartate aminotransferase and bilirubin 2
imes normal, serum creatinine 177 mol/L or cre-
tinine clearance 1.0 mL/s, pulmonary diffusion ca-
acity 50% of predicted, and negative testing for hu-
an immunodeﬁciency virus and hepatitis B surface
ntigens. Exclusion criteria included serious medical or
sychiatric illnesses that would prevent informed con-
able 1. Conditioning Regimen
Day
Dose
mg/m2/d 8 7
otal body irradiation 2 Gy bid X X
yclophosphamide 2000 IV
toposide 600 IV
arboplatin 333 CI
BSC infusion
mifostine* 500 IV X X
The no-amifostine group received the same conditioning regime
infusion; PBSC, peripheral blood stem cells; bid, twice daily.ent or preclude general anesthesia; uncontrolled or f
B&MTevere cardiovascular disease, such as recent myocar-
ial infarction or congestive heart failure within 6
onths of transplantation; active uncontrolled bacte-
ial, viral, or fungal infection; or an active duodenal
lcer. All patients signed informed consent documents
eviewed and approved by the University of North
arolina Committee for the Protection of the Rights
f Human Subjects.
ematopoietic Stem Cells
For patients with NHL or HD, stem cell collec-
ion was accomplished after salvage chemotherapy and
efore initiation of the conditioning regimen. In pa-
ients with AML, stem cells were collected after the
atient achieved CR and underwent at least 1 cycle of
onsolidation chemotherapy. No patient with AML
ad stem cells collected during initial remission for
se after a subsequent relapse. Peripheral blood stem
ells (PBSCs) were used when possible for rescue
herapy. However, if fewer than 2  106 CD34 cells
er kilogram were collected, patients received a com-
ination of marrow and PBSCs or marrow alone as
reviously described [19].
Patients with NHL received pretransplantation
alvage therapy whenever possible to reduce their tu-
or burden before high-dose chemotherapy. Salvage
herapies included ifosfamide, carboplatin, and etopo-
ide [20]; etoposide, methylprednisolone, cytarabine,
nd cisplatin [21]; and dexamethasone, cisplatin, and
ytarabine [22]. High-risk patients with AML received
tem cell transplantation while in CR after initial in-
uction and consolidation or, for relapsed patients,
fter reinduction of remission.
reatment Plan
An indwelling central venous catheter was placed
n all patients before stem cell collection. The condi-
ioning regimen (Table 1). consisted of TBI 2 Gy
wice daily on days 8 through 6 followed by cy-
lophosphamide (total dose, 6 g/m2) and etoposide
total dose, 1.8 g/m2) on days 5 through 3 and a
ontinuous infusion of carboplatin (total dose, 1 g/m2)
5 4 3 2 1 0
X X X
X X X
X X X
X
X X X
without amifostine. IV indicates intravenous; CI, continuous IV6
X
X
n butor 3 days starting on day 5. Amifostine 500 mg/m2
1023
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1as administered once daily on days 8 through 2
s a 3-minute intravenous (IV) push 15 to 30 minutes
efore the morning dose of TBI or ﬁrst daily dose of
hemotherapy. Standard antiemetic therapy was given
efore chemotherapy. Patients received hydration at
50 mL/m2/h during chemotherapy and for a mini-
um of 24 hours after the completion of chemother-
py (ie, throughout days 5 through 1). All patients
eceived granulocyte colony-stimulating factor (G-CSF;
g/kg/d) beginning on day 5 and continuing until
he ANC was 0.5  109/L on 2 consecutive days.
Standard supportive care included ciproﬂoxacin
00 mg orally (PO) twice daily beginning on day 1
nd continuing until body temperature was 38.3°C,
fter which ciproﬂoxacin treatment was discontinued
nd patients received vancomycin 15 mg/kg IV every
2 hours and cefepime 2 g IV every 8 hours. Doses
ere adjusted in the event of renal impairment. Pa-
ients did not routinely receive bladder irrigation or
esna therapy. Fluconazole 400 mg PO once daily
as initiated on day 4, and acyclovir 200 mg PO 3
imes daily was started on day 0 if the patient was
erologically positive for herpes simplex virus. Total
arenteral nutrition (TPN) was used when oral caloric
ntake was inadequate (ie, after a 10% loss in baseline
ody weight or inability to eat solid food for7 days).
tudy End Points
The primary end point was the occurrence and se-
erity of toxicities, particularly mucositis. Mucositis was
raded with the oral mucositis assessment scale [23].
dditional toxicities were assessed according to the Na-
ional Cancer Institute Cancer Therapy Evaluation Pro-
ram Common Toxicity Criteria [24]. Other end points
ncluded the number of days that patients required
PN; the number of days with fever; the number of days
n which antibiotics, narcotics, or G-CSF were admin-
stered; and the total number of days of hospitalization.
linical Response Criteria
A CR was deﬁned as the disappearance of all
easurable disease signs, symptoms, and biochemical
hanges related to the tumor for 4 weeks. No new
esions could have appeared during this time. A partial
esponse was deﬁned as a reduction of 50% in the
um of the products of the perpendicular diameters of
ll measurable lesions that lasted4 weeks and during
hich time no new lesions appeared and no existing
esions enlarged. Stable disease was characterized as
50% reduction and25% increase in the sum of the
roducts of 2 perpendicular diameters of all measured
esions and the appearance of no new lesions for 8
eeks. Progressive disease was deﬁned as an increase
n the product of 2 perpendicular diameters of any
easured lesion by 25% or the appearance of newreas of disease. Increasing symptoms alone did not g
024onstitute progressive disease, although their appear-
nce generated a new evaluation of the extent of dis-
ase. A CR for patients with AML consisted of elim-
nation of all cytogenetic and morphologic evidence of
eukemia with recovery of platelet counts to 50 
09/L without transfusion for a minimum of 30 days
fter transplantation.
tatistical Methods
Descriptive statistics were computed for key out-
ome measures. Where appropriate and available, data
ere compared with those of a historical control
roup—a subset of a previous study in which patients
eceived an identical treatment regimen for their malig-
ancies but did not receive amifostine for cytoprotection
5]. Of the 67 patients in that study, 35 were included in
he historical control group because they received the
ame TBI dose of 12 Gy that was used in this study.
The Fisher exact test was used for data categorized
nto contingency tables to test general associations.
he nonparametric Jonckheere-Terpstra method was
sed to test for ordered differences among categories
for example, the 2  5 renal toxicity table). With this
est, the null hypothesis is that the distribution of the
esponse does not differ across ordered categories. For
ontinuous variables such as days on narcotics, the
ilcoxon rank-sum test (using Van der Waerden nor-
al scores) was used for group comparisons. The
aplan-Meier (or product-limit) method was used to
stimate the overall survivorship, disease-free survi-
orship, and disease progression functions. Statistical
nalyses were performed with SAS statistical software,
ersions 8.2 and 9.1 (SAS Institute Inc., Cary, NC).
ESULTS
atients
Thirty-ﬁve patients with advanced hematologic
alignancies participated in this study between March
999 and December 2002, including 20 with NHL, 12
ith HD, and 3 with AML. There were no signiﬁcant
ifferences in age or sex between the amifostine group
nd the historical control group (no-amifostine
roup), but there were more black patients (P .045),
ore patients with HD or AML (P  .01), more
atients with CR with induction (P .03), and greater
se of PBSCs alone (P  .01) in the amifostine group
han in the no-amifostine group (Table 2).
ematologic Recovery
In the amifostine group, the median time to WBC
ngraftment (ANC0.5 109/L on 2 consecutive days)
as 10 days (range, 8-41 days), and the median time to
latelet engraftment (20  109/L on 2 consecutive
ays) was 11 days (range, 8-40 days). Two patients re-
ained transfusion dependent. In the no-amifostine
roup, the median times to WBC and platelet engraft-
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Bent were 11 and 17 days, respectively. These differ-
nces were not statistically signiﬁcant.
ucositis
All 35 patients (100%) in the amifostine group
xperienced at least grade 1 mucositis. The incidence
f grade 3 or 4 mucositis in the amifostine group was
4 (40%) of 35, including only 2 occurrences (6%) of
rade 4 mucositis (Table 3). The incidence of grade 3
r 4 mucositis in the no-amifostine group was 33
94%) of 35 (P  .0001).
On the basis of criteria set for the study, only 4
atients (11%) in the amifostine group required TPN
or 1, 12, 16, and 17 days (Table 4). In contrast, 34
atients (97%) in the no-amifostine group required
PN (P  .0001) for a median duration of 16 days.
he median duration of narcotic use in patients who
eceived amifostine was 11 days, compared with 15.5
ays in the no-amifostine group (P  .002; Table 4).
enal Toxicity
Normal renal function was preserved in most
atients. Patients who received amifostine had sig-
able 2. Patient Characteristics
Variable Amifo
o. of patients 3
ge, y, median (range) 46 (2
ex, n
Male 22 (6
Female 13 (3
ace, n
Black 9 (2
White 26 (7
retreatment diagnosis, n
Non-Hodgkin lymphoma 20 (5
Hodgkin disease 12 (3
Acute myelogenous leukemia 3 (9
retreatment status, n
Complete remission 16 (4
Partial response 10 (2
Relapse 3 (9
Primary induction failure—sensitive 2 (6
Refractory 4 (1
tem cell source, n
Peripheral blood stem cell 27 (7
Bone marrow 5 (1
Both 3 (9
able 3. Incidence and Duration of Mucositis by Severity in the Amifos
Variable 1
ost severe grade, n 2 (6%)
ny report of mucositis
No. of patients 33 (94%)*
Median duration, d (range)† 6 (2-12)
Two patients had grade 2 mucositis without experiencing grade 1
Among patients reporting that grade of mucositis; does not include 0 da
B&MTiﬁcantly less renal toxicity of any severity (26%)
han those in the no-amifostine group (54%; P 
03; Table 5). Of the patients in the amifostine
roup who were admitted with a normal creatinine
evel, only 9 (26%) developed a creatinine 133
mol/L. One patient was admitted with a creatinine
evel of 159 mol/L and had a peak creatinine level
f 221 mol/L but was discharged with a normal
reatinine level. Another patient was admitted with
creatinine level of 88 mol/L and developed a
eak creatinine level of 345 mol/L. This patient’s
reatinine level remained abnormal during the re-
ainder of the admission, and the patient was dis-
harged with a creatinine level of 292 mol/L.
rade 2 oral mucositis was documented in this
atient, who also received 31 days of antibiotics for
ever without an identiﬁed source.
astrointestinal Toxicity
Gastrointestinal toxicity was recorded only in the
mifostine group. Twenty-two patients (63%) had
rade 1 diarrhea, 12 (34%) had grade 2 diarrhea, and
(3%) had grade 3 diarrhea. The median duration of
No Amifostine P Value
35
47 (19-66) .25
24 (69%) .80
11 (31%)
2 (6%) .045
33 (94%)
30 (86%) .01
5 (14%)
0 (0%)
10 (0%) .03
20 (57%)
0 (0%)
0 (0%)
3 (9%)
20 (57%) .01
2 (6%)
13 (37%)
oup (n  35)
Mucositis Grade
2 3 4
19 (54%) 12 (34%) 2 (6%)
33 (94%) 14 (40%) 2 (6%)
5 (1-12) 4 (1-9) 5 (4-6)
itis.stine
5
1-61)
3%)
7%)
6%)
4%)
7%)
4%)
%)
6%)
6%)
%)
%)
1%)
7%)
4%)tine Gr
mucos
ys.
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1rade 1 or 2 diarrhea was 3 days (range, 1-7 days).
ausea and vomiting occurred in most patients, but
hese were usually transient and were not dose limit-
ng. Delayed nausea or vomiting occurred in 3 pa-
ients (9%): 2 (6%) had grade 2 and 1 (3%) had grade
. No patient had grade 4 gastrointestinal toxicities.
mifostine Side Effects
No case of nausea, hypotension, or hypocalcemia
ore severe than grade 1 was observed in the amifos-
ine group. Nearly all patients had signiﬁcant nausea,
ut none required intervention with more than anti-
metics. Intravenous calcium replacement was pro-
ided as needed after corrections for hypoalbumine-
ia were made.
ther Outcomes and Events
Infections documented by microbiological culture
ccurred in 13 patients (37%) in the amifostine group
nd included 6 (17%) with bacteremia, 1 (3%) with
enitourinary infection, 1 (3%) with pleural ﬂuid, and
(6%) with vancomycin-resistant enterococcal infec-
ions. In addition, 1 patient with AML had a pulmo-
ary aspergillus infection documented before trans-
lantation; he was treated prophylactically with
ntifungal agents, and his fungal infection was not
eactivated. Finally, 1 patient developed reactivation
f varicella-zoster virus, and 1 had herpes simplex
irus 2.
Comparison of the pretreatment and posttreat-
ent left ventricular ejection fraction within each
roup and between groups almost reached statistical
igniﬁcance when the absolute changes from baseline
alues were compared (P  .06) and when the per-
entage changes from baseline were compared (P 
able 4. Mucositis Associated with Combined-Modality Chemoradiother
retreatment
Variable
ucositis grade 3 or 4, n
edian (range) duration of narcotic use for mucositis, d
equired TPN, n
able 5. Renal Toxicity Associated with Combined-Modality
hemoradiotherapy before Autologous Stem Cell Transplantation, with
r without Amifostine Pretreatment
Variable
Amifostine
(n  35)
No Amifostine
(n  35) P Value
o toxicity, n 26 (74%) 16 (46%)
ny grade, n 9 (26%) 19 (54%) .03
Grade 1 5 (14%) 11 (31%)
Grade 2 4 (11%) 4 (11%)
Grade 3 0 (0%) 1 (3%)i
Grade 4 0 (0%) 3 (9%) .02
02606) between patients who received amifostine and the
o-amifostine group.
The values for hematocrit and volume-corrected
iffusion capacity (carbon monoxide diffusion in the
ung) were similar from baseline to the ﬁnal visit in
oth groups and were not signiﬁcantly different be-
ween the amifostine and no-amifostine groups. Only
serious adverse events were reported in the amifos-
ine group, and both were cardiac in origin. One
atient had a grade 3 cardiac arrhythmia that was
elated to the conditioning regimen, and the patient
ecovered uneventfully. The other patient had a mod-
rately large pericardial effusion that also resolved
neventfully.
In the amifostine group, there were 12 deaths, and
he median follow-up time in survivors was 26 months
Figure 1). Disease progression occurred in 15 pa-
ients.
ISCUSSION
In this study, amifostine administered at a dose of
00 mg/m2/d for 7 days during a conditioning regi-
en that included high-dose chemotherapy and TBI
efore hematopoietic stem cell transplantation sub-
tantially reduced the incidence and severity of mu-
ositis compared with results obtained previously in
atients treated with an identical regimen minus ami-
igure 1. Probability (and 95% conﬁdence interval) of overall
urvival among patients who received amifostine during condition-
ore Autologous Stem Cell Transplantation, with or without Amifostine
Amifostine
(n  35)
No Amifostine
(n  35) P Value
14 (40%) 33 (94%) <.0001
11 (1-23) 15.5 (5-48) .002
4 (11%) 34 (97%) <.0001apy befng therapy.
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Bostine [5]. The incidence of severe (grade 3 or 4)
ucositis in the earlier study was more than 2-fold
igher than when amifostine was included. Because
he oral manifestations of mucositis are very painful
nd interfere with nutrition, the observed difference
n mucositis rates with or without amifostine treat-
ent accounted for signiﬁcant reductions in the num-
er of patients who required TPN (11% versus 97%)
nd the median duration of narcotic use (11 versus
5.5 days).
Amifostine administration was associated with
ild and transient side effects (nausea, vomiting, hy-
otension, and hypocalcemia) in most, but not all,
atients, but these effects did not cause interruption of
herapy in any patient. Similar response rates and
ngraftment times were observed when comparing
atients who were treated with the conditioning reg-
men with and without amifostine. The risk for tumor
rotection when cytoprotective agents are adminis-
ered during chemotherapy has been a theoretical ar-
ument against the use of drugs to protect healthy
issue. In the case of amifostine, previous study results
ave shown no evidence of tumor protection [17,18].
he results presented here suggest that amifostine is
ssociated with selective protection from mucositis
ithout signiﬁcant tumor protection. However, differ-
nces in disease characteristics and treatment regimens
ere observed between the amifostine and no-amifostine
roups at baseline. Therefore, conﬁrmation of these
esults with a prospective, randomized, controlled trial
s warranted. In light of the striking differences ob-
erved between the amifostine group and the histori-
al control group in this retrospective analysis, pro-
pective trials in this setting should include clearly
eﬁned rules for stopping the trial early if interim
nalyses demonstrate evidence of cytoprotection with
mifostine compared with the control group. Innova-
ive study designs, such as the identiﬁcation and use of
urrogate markers for treatment toxicities, might also
e useful for identifying the response to amifostine
ore clearly and more rapidly.
The results of this study are consistent with those
f other published studies demonstrating that amifos-
ine can provide selective cytoprotection for healthy
issues in patients undergoing myeloablative condi-
ioning regimens before stem cell transplantation. In a
andomized trial, 40 patients with solid tumors under-
oing autologous PBSC transplantation received
igh-dose carboplatin-based chemotherapy (carbopla-
in, ifosfamide, and etoposide) with or without ami-
ostine (910 mg/m2) [25]. All patients received G-
SF. Nephrotoxicity and gastrointestinal toxicity
ere substantially diminished in patients who received
mifostine. For example, amifostine signiﬁcantly re-
uced the incidence of mucositis (P  .01) and diar-
hea (P  .01). Amifostine-treated patients also had
ewer days with fever, more rapid hematologic recov- t
B&MTry, and earlier discharge from the hospital; this re-
ulted in a cost savings of approximately 30% for
upportive care [25]. However, Chauncey et al. [26]
id not ﬁnd a beneﬁt to the use of amifostine. They
valuated 21 patients conditioned with busulfan, mel-
halan, and thiotepa who were also treated with ami-
ostine only during melphalan and thiotepa treatment
fter completion of the busulfan portion of condition-
ng. The lack of beneﬁt observed for the reduction of
onhematologic toxicities in that study may have re-
ulted because amifostine was not also included during
usulfan administration. Mucositis associated with the
ombination of radiation and carboplatin in a random-
zed trial for the treatment of head and neck cancer
as signiﬁcantly reduced by the infusion of amifostine
00 mg/m2 before radiation administration [27]. Be-
ause of fewer treatment interruptions, the treatment
uration was signiﬁcantly shorter in the amifostine
roup (P  .01). At week 5, grade 4 mucositis was
resent in 52.2% of patients in the control group but
n only 4.5% of patients treated with amifostine (P 
0006) [27]. It should also be pointed out that the
heoretical risks of tumor protection by the adminis-
ration of amifostine were not observed in any of the
rials listed previously nor in the study reported here.
A reduction in the severity of mucositis may per-
it more intensive chemoradiotherapy. Phillips [15]
sed amifostine to minimize mucositis in a dose-esca-
ation trial in which melphalan was increased from 200
o 280 mg/m2. Thieblemont et al. [28] reported a
eduction in mucositis from 65% without amifostine
o 33% with amifostine 740 mg/m2. Capelli et al. [29]
lso reported a reduction in grade 3 or 4 mucositis
rom 53% in the control group to 21% in the treat-
ent group when amifostine was given with melpha-
an; reductions in the duration of narcotic use and
iarrhea were also reported. In another randomized
tudy of 46 patients with stage II and III multiple
yeloma treated with amifostine before a condition-
ng regimen that included high-dose melphalan and
usulfan, patients were randomized to receive amifos-
ine 740 mg/m2 or no amifostine before melphalan.
he treatment group had a 13% incidence of World
ealth Organization grade 3 and 4 mucositis, com-
ared with 35% in patients who did not receive ami-
ostine [30].
Severe mucositis can have a profound adverse ef-
ect during blood or marrow transplantation, and in
any cases, mucositis limits treatment intensity [5].
ral mucositis presents particular problems in pain
anagement, reduces nutrition, limits patient com-
unication, and increases infection risk [31-37]. The
uration of oral mucositis in transplantation is typi-
ally 3 to 9 days [4], and 50% of patients develop grade
to 4 mucositis [6]. The variability in the severity of
ucositis is thought to be related to the intensity ofhe conditioning regimen, cytokine production during
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1onditioning, alteration of microbial ﬂora, antimicro-
ial drugs, direct effects of chemotherapy, and stem
ell source [6,38-41]. Other contributing factors in-
lude reductions in the volume of saliva and reduc-
ions in the salivary immunoglobulin concentration
42].
The mechanism of action of amifostine to di-
inish the severity and occurrence of mucositis is
urrently not clear. Sonis [2,43] proposed a 5-step
odel for the evolution of mucositis (Figure 2). The
rst phase of this model is the initiation phase, in
hich healthy tissue sustains damage to both nu-
lear and cytoplasmic elements. The second phase,
eferred to as the message-generation phase, begins
ith interference of cellular control mechanisms. It
s postulated that the institution of chemotherapy or
adiotherapy leads to activation of transcription fac-
ors, including nuclear factor B, that in turn acti-
ate many genes [44]. During this phase, ceramide-
nduced apoptosis in mucosal endothelial cells
ccurs [45]. The message-generation phase is fol-
owed by the signaling and ampliﬁcation phase, in
hich inﬂammatory cytokines are produced [44].
he appearance of the ulceration phase marks the
ost clinically signiﬁcant period of mucositis. Dur-
ng this time, pseudomembranes and bacteria over-
rowth appear. Pain during this phase may inhibit
honation and food ingestion. Bacteria may pene-
rate into the submucosa and result in bacteremia
46]. The healing phase is heralded by the migration
f epithelial cells into the ulcer to restore normal
ucosal contours that then decrease pain.
The mechanism of action for amifostine may tar-
et several points in this model. Its initial effect is
ikely to occur during the tissue damage phase, when
t scavenges reactive intermediates generated by ther-
py [47]. The symmetric disulﬁde dimeric form of
igure 2. Pathobiology of mucositis. Mucositis is thought to occur
ignaling and ampliﬁcation, ulceration, and healing. Possible act
ntermediates generated by radiotherapy and chemotherapy in the in
f amifostine at other phases in this model [47,49]. Reprinted withmifostine, which is in equilibrium with the parent s
028ompound in the plasma and is structurally similar to
he polyamine, spermidine, may also be important at
ther points in this model [47]. The ability of amifos-
ine to modulate the intracellular oxidative state seems
o be related to its activation of nuclear factor B,
uperoxide dismutase, and p53 [47-49]. These factors
ay be important for cytoprotection and antitumor
ffects [48].
Severe mucositis adds substantial costs to patient
reatment [50,51]. In general, mucositis is associated
ith longer hospitalization, longer need for TPN,
onger use of narcotics, and increased 100-day mor-
ality [51]. In an economic analysis by Bennett and
olleagues [50] of a small randomized trial that used
mifostine to reduce mucositis, a highly signiﬁcant
eduction in the severity of thrombocytopenia and
erostomia was observed that was calculated to yield
n overall reduction in the cost of the transplantation.
similar analysis by Sonis and colleagues [51] also
ndicated a signiﬁcant increase in costs when mucositis
ccurred.
Careful mouth care is an essential element in the
anagement of oral mucositis [52]. The use of topical
ntibiotics [46], phototherapy [53,54], and oral rinses
ontaining interleukin 11 and granulocyte-macroph-
ge colony-stimulating factor [55,56] have been dis-
ppointing. However, subcutaneously injected kera-
inocyte growth factor does seem to reduce the
ncidence of mucositis [57,58].
In summary, a considerable amount of data on the
se of amifostine in patients undergoing myeloabla-
ive regimens before stem cell transplantation, includ-
ng the results from this study, demonstrates that
mifostine treatment can reduce the toxicities associ-
ted with conditioning therapy during autologous
tem cell transplantation. Randomized, comparative
linical trials with innovative study designs and clear
ollowing 5 phases: initiation, upregulation and message generation,
f amifostine to reduce mucositis include scavenging of reactive
phase, as well as activity of the symmetric, disulﬁde, dimeric form
ssion of McNeil-PPC, Inc. [2].in the f
ions o
itiationtopping rules are warranted to establish the cytopro-
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Amifostine in Autologous Stem Cell Transplantation
Bective beneﬁts of amifostine when it is used with a
onditioning regimen before autologous stem cell
ransplantation.
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